A study to assess the efficacy, safety, pharmacokinetics and related genetic polymorphisms of afatinib
Not Applicable
- Conditions
- adenocarcinoma of the lung
- Registration Number
- JPRN-UMIN000014237
- Lead Sponsor
- aboratoly of Pharmacy Practice and Social Science, Gifu Pharmaceutical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 43
Inclusion Criteria
Not provided
Exclusion Criteria
No exclusion criteria
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess PK/PD based on plasma concentration of afatinib, as well as efficacy and safety.
- Secondary Outcome Measures
Name Time Method To explore genetic polymorphisms relating to pharmacokinetics, efficacy, and safety of afatinib.